Current concepts and review of pimecrolimus in the treatment of psoriasis.
Wolff
Klaus
K
Department of Dermatology, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, Vienna A-1090, Austria. klaus.wolff@akh-wien.ac
D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D020714:Maximum Tolerated Dose; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D018570:Risk Assessment; D012720:Severity of Illness Index; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus